About this trial
Study to evaluate the diagnostic precision of ICG and 99mTc nanocolloid albumin in sentinel lymph node detection in early ovarian epithelial cancer.
Eligibility criteria
Qualifiers
Patients with adnexal mass diagnosed with high suspicion of malignancy that will undergo intraoperative biopsy or patients with already diagnosed epithelial cancer in early stages in a previous surgery and confirmed by pathology with complete staging indicated.
Absence of retroperitoneal ganglionary affectation and metastatic disease evaluated by preoperative imaging techniques.
Signing of informed consent by the patient or relative in charge.
Women with childbearing potential must compromise to use highly effective contraceptive methods (partner vasectomized, sexual abstinence) until the end of the study (last study visit).
Disqualifiers
Patients <18 years
Pregnancy or breastfeeding
Epithelial ovarian tumors stage FIGO III or IV.
Impossibility to obtain a biopsy from the tumor.
Trial design
Treatments tested in this trial
- 99mTC nanocolloid albumin injection
- ICG injection